BACKGROUND: Tobacco use is a leading cause of premature death, yet few studies have investigated the effect of tobacco exposure on the outcome of patients with renal cell carcinoma (RCC). The authors of this report retrospectively studied the impact of smoking on clinicopathologic factors, survival outcomes, and p53 expression status in a large cohort of patients with RCC. METHODS: Eight hundred-two patients (457 nonsmokers and 345 smokers) who had up to 232 months of follow-up were compared for differences in their clinicopathologic features and survival outcomes. Immunohistochemical differences in p53 expression were correlated with smoking status. RESULTS: Smokers presented more commonly with pulmonary comorbidities (P < .0001) and cardiac comorbidities (P = .014) and with a worse performance status (P = .031) than nonsmokers. Smoking was associated significantly with tumor multifocality (P = .022), higher pathologic tumor classification (P = .037), an increased risk of bulky lymph node metastases (P = .031), and the presence of distant metastases (P < .0001), especially lung metastases (P < .0001). Both overall survival (OS) (62.37 months vs 43.64 months; P = .001) and cancer-specific survival (CSS) (87.43 months vs 56.57 months; P = .005) were significantly worse in patients who smoked. The number of pack-years was retained as an independent predictor of CSS and OS in patients with nonmetastatic disease. Mean expression levels of p53 were significantly higher in current smokers compared with former smokers and nonsmokers (P = .012). CONCLUSIONS: In patients with RCC, a history of smoking was associated with worse pathologic features and survival outcomes and with an increased risk of having mutated p53. Further investigation of the genetic and molecular mechanisms associated with decreased CSS in patients with RCC who have a history of smoking is indicated.
BACKGROUND:Tobacco use is a leading cause of premature death, yet few studies have investigated the effect of tobacco exposure on the outcome of patients with renal cell carcinoma (RCC). The authors of this report retrospectively studied the impact of smoking on clinicopathologic factors, survival outcomes, and p53 expression status in a large cohort of patients with RCC. METHODS: Eight hundred-two patients (457 nonsmokers and 345 smokers) who had up to 232 months of follow-up were compared for differences in their clinicopathologic features and survival outcomes. Immunohistochemical differences in p53 expression were correlated with smoking status. RESULTS: Smokers presented more commonly with pulmonary comorbidities (P < .0001) and cardiac comorbidities (P = .014) and with a worse performance status (P = .031) than nonsmokers. Smoking was associated significantly with tumor multifocality (P = .022), higher pathologic tumor classification (P = .037), an increased risk of bulky lymph node metastases (P = .031), and the presence of distant metastases (P < .0001), especially lung metastases (P < .0001). Both overall survival (OS) (62.37 months vs 43.64 months; P = .001) and cancer-specific survival (CSS) (87.43 months vs 56.57 months; P = .005) were significantly worse in patients who smoked. The number of pack-years was retained as an independent predictor of CSS and OS in patients with nonmetastatic disease. Mean expression levels of p53 were significantly higher in current smokers compared with former smokers and nonsmokers (P = .012). CONCLUSIONS: In patients with RCC, a history of smoking was associated with worse pathologic features and survival outcomes and with an increased risk of having mutated p53. Further investigation of the genetic and molecular mechanisms associated with decreased CSS in patients with RCC who have a history of smoking is indicated.
Authors: Harun Fajkovic; Shahrokh F Shariat; Tobias Klatte; Mihai Dorin Vartolomei; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Alberto Briganti; Pierre I Karakiewicz; Vitaly Margulis; Michael Rink; Mesut Remzi; Christian Seitz; Karim Bensalah; Romain Mathieu Journal: World J Urol Date: 2016-02-15 Impact factor: 4.226
Authors: Michael Rink; Evanguelos Xylinas; Vitaly Margulis; Eugene K Cha; Behfar Ehdaie; Jay D Raman; Felix K Chun; Kazumasa Matsumoto; Yair Lotan; Helena Furberg; Marek Babjuk; Armin Pycha; Christopher G Wood; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-06-22 Impact factor: 20.096
Authors: Seung Hee Choi; Jeffrey E Terrell; Carol R Bradford; Tamer Ghanem; Matthew E Spector; Gregory T Wolf; Isaac M Lipkus; Sonia A Duffy Journal: Nicotine Tob Res Date: 2016-08-18 Impact factor: 4.244
Authors: James Reigle; Dina Secic; Jacek Biesiada; Collin Wetzel; Behrouz Shamsaei; Johnson Chu; Yuanwei Zang; Xiang Zhang; Nicholas J Talbot; Megan E Bischoff; Yongzhen Zhang; Charuhas V Thakar; Krishnanath Gaitonde; Abhinav Sidana; Hai Bui; John T Cunningham; Qing Zhang; Laura S Schmidt; W Marston Linehan; Mario Medvedovic; David R Plas; Julio A Landero Figueroa; Jarek Meller; Maria F Czyzyk-Krzeska Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808
Authors: Daniel Keizman; Maya Gottfried; Maya Ish-Shalom; Natalie Maimon; Avivit Peer; Avivit Neumann; Hans Hammers; Mario A Eisenberger; Victoria Sinibaldi; Roberto Pili; Henry Hayat; Svetlana Kovel; Avishay Sella; Ben Boursi; Rony Weitzen; Wilmosh Mermershtain; Keren Rouvinov; Raanan Berger; Michael A Carducci Journal: Oncologist Date: 2013-12-05